Immediate Impact
1 by Nobel laureates 1 from Science/Nature 58 standout
Citing Papers
GPCR drug discovery: new agents, targets and indications
2025 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Works of Simin Baygani being referenced
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
2013
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial
2002
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Simin Baygani | 197 | 104 | 78 | 123 | 116 | 36 | 605 | |
| M.B. Siroky | 332 | 85 | 27 | 236 | 138 | 26 | 679 | |
| Tae-Kon Hwang | 129 | 111 | 16 | 393 | 191 | 24 | 654 | |
| Magnus Fovaeus | 94 | 48 | 34 | 319 | 60 | 23 | 542 | |
| Dirk‐Henrik Zermann | 121 | 169 | 17 | 275 | 165 | 48 | 616 | |
| Fabiano Beraldi Calmasini | 128 | 46 | 47 | 244 | 78 | 49 | 636 | |
| Fábio Henrique Silva | 224 | 36 | 42 | 242 | 61 | 46 | 636 | |
| Hans Jørgen Kirkeby | 373 | 126 | 56 | 320 | 161 | 34 | 667 | |
| Ahmet Erbağcı | 75 | 97 | 39 | 159 | 69 | 50 | 735 | |
| Nancy S. Day | 164 | 63 | 29 | 219 | 38 | 27 | 542 | |
| Brian L. Cohen | 93 | 111 | 18 | 261 | 252 | 31 | 672 |
All Works
Loading papers...